EDT — Spectral Medical Share News
0.000.00%
Last trade - 00:00- CA$324.10m
- CA$348.98m
- CA$2.44m
Brief: Spectral Medical Provides Update On Tigris Clinical Trial
Brief: U.S. FDA Grants Spectral Medical Breakthrough Device Designation For Toraymyxin
Brief: Spectral Medical Announces Adoption Of SAMI Device By Largest Inpatient Dialysis Provider In South Florida
Brief: Spectral Medical Appoints Industry Executive Sam Amory As Dialco President
Brief: Spectral Announces First Quarter Results And Provides Corporate Update
Brief: Spectral Medical Inc Says Loss For Quarter Ended December 31, 2021 Was $0.010 Per Share
Brief: Spectral Medical Appoints Blair McInnis As CFO
Brief: Spectral Medical Announces U.S. FDA Approval Of DIMI Trial Protocol Amendment
Brief: Spectral Medical Announces U.S. FDA Approval Of Tigris Trial Protocol Amendment To Expand Inclusion Criteria
Brief: Spectral Medical Q3 Loss Per Share C$0.008
Brief: Spectral Announces Q2 Results
Brief: Spectral Medical Announces $10 Million Offering
Brief: Spectral Medical Inc. Announces Overnight Marketed Offering
Brief: Dialco Medical Inc. Engages Cromsource As Contract Research Organization Partner For Dimi Ide Trial
Brief: Spectral Announces First-Quarter Results, Provides Corporate Update
Brief: Spectral Medical’S Wholly-Owned Subsidiary Dialco Medical Announces Receipt Of Health Canada License For Dimi
Brief: Spectral Announces Fourth Quarter And Fiscal 2020 Results
Brief: Spectral Medical Names Chris Seto To As CEO
Brief: Spectral Medical Says Unit Dialco Medical Granted FDA IDE Authorization To Conduct Trial Of DIMI For Home Hemodialysis Use